Voyager Therapeutics (VYGR) said Wednesday it selected its lead development candidate for tau silencing gene therapy program in Alzheimer's disease and expects to file regulatory applications for the candidate in the US and Canada in 2026.
The company said that the candidate, VY1706, showed reductions in levels of tau - the protein that contributes Alzheimer's if accumulated abnormally - by 50% to 73% across the brain in a non-human primate study.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments